Antioxidants · 2024 · 10 citations · 25 references
Life SciencesBiochemistryPharmacologyInflammationLipid BiochemistryMetabolic RegulationAnti-inflammatory PharmacologyHepatic PathophysiologyLipid MetabolismLipoprotein MetabolismLiver DiseaseMetabolic InflammationBiochemical PathologyEndoplasmic Reticulum Phospholipid MetabolismHepatic Lipid AccumulationHistopathological BiomarkersHistopathological EvaluationLipid AccumulationNonalcoholic Fatty Liver Disease-associated Insulin ResistanceUnfolded Protein Response
Nonalcoholic steatohepatitis (NASH) is a critical stage in the progression of nonalcoholic fatty liver disease (NAFLD). Tanshinone IIA (TIIA) is a tanshinone extracted from Salvia miltiorrhiza; due to its powerful anti-inflammatory and antioxidant biological activities, it is commonly used for treating cardiovascular and hepatic diseases. A NASH model was established by feeding mice a methionine and choline-deficient (MCD) diet. Liver surface microblood flow scanning, biochemical examination, histopathological examination, cytokine analysis through ELISA, lipidomic analysis, transcriptomic analysis, and Western blot analysis were used to evaluate the therapeutic effect and mechanism of TIIA on NASH. The results showed that TIIA effectively reduced lipid accumulation, fibrosis, and inflammation and alleviated endoplasmic reticulum (ER) stress. Lipidomic analysis revealed that TIIA normalized liver phospholipid metabolism in NASH mice. A KEGG analysis of the transcriptome revealed that TIIA exerted its effect by regulating the PPAR signalling pathway, protein processing in the ER, and the NOD-like receptor signalling pathway. These results suggest that TIIA alleviates NASH by activating the PPARα/FGF21 axis to negatively regulate the ER stress-induced unfolded protein response (UPR).
25
Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD
Alexandra Montagner, Arnaud Polizzi, Edwin Fouché et al. · Gut · 2016 · 731 citations · Full text
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Sven Francque, Pierre Bédossa, Vlad Ratziu et al. · New England Journal of Medicine · 2021 · 721 citations · Full text